Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Phase 3 CAPTIVATE CIDP trial ongoing ... but not limited to, that preclinical testing of DNTH103 and data from clinical trials may not be predictive of the results or success of ongoing or ...

US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase ...

Thanks for the question about CIDP launch. As I shared ... the DOK7 mutation in human beings and that's exactly what we're testing for CMS. Think of a genetic form of MG which has overlapped ...

Phase 3 CAPTIVATE CIDP trial ongoing: The CAPTIVATE trial is a single ... but not limited to, that preclinical testing of DNTH103 and data from clinical trials may not be predictive of the results or ...

In lieu of flowers, donations may be made to the Guillain-Barre Syndrome at the GBS/CIDP Foundation International, 375 East Elm Street, Suite 101, Conshohocken, PA 19428. May his memory be a blessing.

The aim of the questionnaire was to understand how many patients with CIDP who did not respond to IVIG therapy the healthcare professionals followed, how many of these patients had had genetic testing ...

Which of the statements below about the study on the impact of the COVID-19 pandemic on the mental health of patients with chronic inflammatory demyelinating polyneuropathy (CIDP ... how well you ...

These include myasthaenia gravis, chronic inflammatory demyelinating polyneuropathy and immune thrombocytopaenia. Seismic Therapeutic plans to test the drug's efficacy as a chronic and acute ...

And of course while CIDP is not on the NRDL ... Nevertheless, we are going to test the combination with carbo and then we will have to select the dose for ZL-1310 with that combination.

Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting ...